Avantax Advisory Services’s PTC Therapeutics PTCT Stock Holding History

Avantax Advisory Services’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$445K	Hold	9,104	–	–	﹤0.01%	1655
2025 Q1	$464K	Hold	9,104	–	–	﹤0.01%	1551
2024 Q4	$411K	Hold	9,104	–	–	﹤0.01%	1573
2024 Q3	$338K	Buy	9,104 +16	+0.2%	+$536	﹤0.01%	1670
2024 Q2	$278K	Buy	9,088 +9	+0.1%	+$292	﹤0.01%	1744
2024 Q1	$264K	Hold	9,079	–	–	﹤0.01%	1374
2023 Q4	$250K	Hold	9,079	–	–	﹤0.01%	1339
2023 Q3	$203K	Hold	9,079	–	–	﹤0.01%	1426
2023 Q2	$369K	Buy	+9,079	New	+$444K	﹤0.01%	1079
2020 Q4	–	Sell	-9,379	Closed	-$438K	–	1254
2020 Q3	$438K	Buy	+9,379	New	+$462K	0.01%	848

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avantax Advisory Services's PTCT Position: Q2 2025 in Review

Avantax Advisory Services held its PTC Therapeutics (PTCT) position steady in Q2 2025 at 9,104 shares worth $445K. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

Avantax Advisory Services first reported a position in PTCT in Q3 2020 and has held it in 10 quarters since. The position peaked at $464K in Q1 2025. 283 funds tracked by Wall St. Rank hold PTCT as of Q2 2025.

Avantax Advisory Services held 9,104 shares of PTC Therapeutics worth $445K as of Q2 2025.
Avantax Advisory Services left its PTC Therapeutics share count unchanged in Q2 2025.
PTC Therapeutics made up ﹤0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #1655 holding.
Avantax Advisory Services first reported a position in PTC Therapeutics in Q3 2020 and has held it in 10 quarters since.
Avantax Advisory Services's PTC Therapeutics position peaked at $464K in Q1 2025.
283 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.